UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

July 1, 2016

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 
 

 

 

  

 

 

Status regarding Novo Nordisk's holding of its own shares (30 June 2016)

  

Bagsværd, Denmark, 1 July 2016 – In continuation of the company's announcements dated 3 February 2016 and 29 April 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly- owned affiliates on 30 June 2016 owned 18,377,645 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 3,675,529 or 0.7% of the total share capital.

 

In the second quarter of 2016 a total of 9,932,000 B shares were repurchased, and 227,000 B shares were disposed to employees in connection with employee incentive programmes.

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 

Further information

Media:    
Katrine Sperling  +45 3079 6718  krsp@novonordisk.com
Ken Inchausti (US)   +1 609 786 8316  kiau@novonordisk.com
     
Investors:     
Peter Hugreffe Ankersen  +45 3075 9085  phak@novonordisk.com
Melanie Raouzeos  +45 3075 3479  mrz@novonordisk.com
Kasper Veje (US)  +1 609 235 8567  kpvj@novonordisk.com 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 49 / 2016

 

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: July 1, 2016

 

NOVO NORDISK A/S

 

Lars Rebien Sørensen,

Chief Executive Officer